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1. The Blood-Brain Barrier
The blood–brain barrier (BBB) is a dynamic interface that sepa-
rates the central nervous system (CNS) from the circulatory sys-
tem, maintaining homeostasis in the neurological niche, which
is easily affected by fluctuations in the con-
centration of small molecules and metabo-
lites and protecting neurons from
pathogenic agents present in the blood-
stream. This barrier is formed by a series
of unique properties of the nonfenestrated
brain microvascular endothelial cells
(BMECs), namely the tight junctions
between BMECs which form a diffusion
barrier limiting paracellular movement,
as well as the enzymatic barriers and
increased expression of efflux transporters
and pumps, which regulate the transcellu-
lar transport.[1,2] All these characteristics
come together to form a diffusion barrier
which impedes the influx of most com-
pounds into the brain, including most
drugs targeting the brain with a molecular
mass over 400 Da.[3] While the major com-
ponent of the BBB are the BMECs, the
properties that allow BMECs to exert this
barrier function are not intrinsic to the cells
but are induced through their interaction
with other cell types found in close association with the brain
microvasculature.[4–6] This complex, well-organized multicellular
anatomic structure is known as the neurovascular unit (NVU).
The NVU consists of BMECs, pericytes, astrocytes, microglia,
and their shared acellular basement membrane (BM),
which together ensheath the brain microvasculature and are
thought to establish and maintain the BBB, as shown in
Figure 1.[4,7,8]
The components of the NVU secrete biochemical factors and
provide mechanical support required to maintain barrier integ-
rity, as shown in Figure 2. Astrocytes play a key role in the devel-
opment and maintenance of the BBB, partially by releasing
growth factors, through both their direct interaction with
endothelial cells and their secretory protein communication,
resulting primarily in a restricted permeability through tight
junctions.[4,9–12] While defining the role of astrocytes has histori-
cally been successful, and thus their importance in the NVU
inflated, finding the exact role of pericytes within the NVU is
challenging. This is as there is currently no distinct pericyte-
specific marker, although extensive pericyte recruitment is a
hallmark of a functional BBB.[13,14] However, in early BBB devel-
opment, the adhesion between BMECs and pericytes has been
hypothesized to release chemotactic factors from the BMECs
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Central nervous system (CNS) pathologies are a prevalent problem in aging
populations, creating a need to understand the underlying events in these dis-
eases and develop efficient CNS-targeting drugs. The importance of the blood–
brain barrier (BBB) is evident, acting both as a physical barrier to drug entry into
the CNS and potentially as the cause or aggravator of CNS diseases. The
development of a biomimetic BBB in vitro model is required for the under-
standing of BBB-related pathologies and in the screening of drugs targeting the
CNS. There is currently great interest in understanding the influence of bio-
chemical and biophysical factors, as these have the potential to greatly improve
the barrier function of brain microvascular endothelial cells (BMECs). Recent
advances in understanding how these may regulate barriergenesis in BMECs
help promote the development of improved BBB in vitro models and therefore
novel interventional therapies for pathologies related to its disruption. Herein, an
overview of specific biochemical and biomechanical cues in the formation of the
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to induce the migration of pericytes to the endothelial wall and
subsequent maturation of the vessels via the increased
production of ECM components through the activation of
growth factors such as the transforming growth factor (TGF)-β
and platelet-derived growth factor (PDGF).[7,15–17] The BM is
an important acellular component of the NVU that provides
mechanical support to BMECs and acts as a reservoir of growth
factors secreted by the surrounding cells, which strongly influ-
ences BBB integrity.[18,19]
Neurological diseases, such as neurodegenerative diseases,
infection, pain, and psychiatric disorders, are the leading cause
of disability, morbidity, and mortality worldwide.[20,21] As the
BBB prevents most therapeutic agents from entering the brain,
the lack of a priori knowledge of drug delivery kinetics to the
brain remains a bottleneck in the development of CNS thera-
pies.[3,20,22,23] A notable example is glioblastoma, a particularly
deadly and very aggressive cancer which begins within the brain,
whose treatment is ineffective in part due to the inability of
chemotherapeutic drugs from reaching the tumor site due to
the BBB.[24] This is additionally accompanied with changes in
the NVU near the tumor site, such as altered junctional protein
expression, loss of astrocytic end feet, and increased permeabil-
ity.[25] There is further correlation between the disruption of the
BBB and pathologies such as Alzheimer’s, multiple sclerosis,
and Parkinson’s.[26–28] For example, a breakdown of the primary
tight junction (TJ) seal proteins, claudins, between BMECs has
been demonstrated in stroke and inflammation.[2,29]
This results in delayed and extended drug development time-
lines and a high failure rate of related clinical trials.[30] As a result,
the need for an accurate and physiological in vitro model of the
BBB has become an indispensable pursuit, to model CNS pathol-
ogies and test the BBB-penetrating potential of novel drugs.
Advances in bioengineering, stem cell technology, microflui-
dics, as well as general knowledge of the CNS microvasculature
have led to rapid advances in the development of in vitro BBB
models capable of exhibiting a wide range of in vivo-like BBB
properties, although no current model is capable of reproducing
the full range of physiological functions and responses or main-
taining a stable barrier function.[31–34] Importantly, BMECs are
capable of sensing the mechanical stimuli exerted by blood flow,
resulting in cytoskeleton rearrangement and impacting BBB
function.[35,36] The value of an in vitro BBB model resides in
its ability to recapitulate the in vivo and ex vivo properties and
its ability to facilitate CNS drug discovery and develop novel
CNS therapeutics.
The current models can be categorized in four general arche-
types: 1) the Transwell model, 2) microfluidic chips, 3) spheroid-
based models, and 4) hydrogel-laden microfluidic chips.[33]
Within these models, the BMECs are exposed to numerous bio-
chemical signals, in the form of cell culture media composition
and extracellular matrix (ECM) protein coatings, as well as
mechanical cues, such as fluid flow and substrate/scaffold phys-
ical properties and architecture, all of which impact barrier for-
mation. While shear stress and biochemical in vitro signaling
have been well reported, the impact of matrix-induced mechani-
cal signaling is somewhat less discussed. Furthermore, some of
the common pitfalls of these models involve the use of substrates
that poorly represent the native BMEC environment in terms of
mechanical stiffness, protein composition, and potentially cell
curvature. In addition, while complex co- or triculture conditions
offer tighter barriers, there remain gaps in the literature on the
core required biochemical signals that can entirely skip the use of
cocultures with BMECs.
While there remains a long way for in vitro BBB models to go,
some innovative microfluidic devices can overcome these pitfalls,
both mimicking the 3D geometry and cell curvature of the BBB
in combination with shear stress.[34,37] In the model described by
Campisi et al., increasing complexity models are created with the
addition of pericytes and pericytes plus astrocytes, which were
shown to self-assemble into microvessels of increasing BBB
characteristics with the addition of further cell lines.[34] This
model has limited applicability as a drug permeability model,
as the polydimethylsiloxane (PDMS), a widely used polymer in
microfluidic applications, shows a nonspecific protein adsorp-
tion behavior. As testing the barrier permeability is limited in
this model, it is additionally a shame that transendothelial elec-
trical resistance (TEER) measurements are another metric of the
BBB function, which this model does not currently support.
Furthermore, the general complexity of the model, with the
use of triculture conditions and iPSCs to achieve BBB character-
istics, may limit its usability by the average lab or medical center,
and therefore the use of BBB-inducing mechanisms aside from
coculture may be helpful.
Creating relevant BBB models requires an understanding of
the complex in vivo CNS microcapillaries, as well as the dynamic
microenvironment that surrounds the BBB and maintains or dis-
rupts its barrier integrity.[38] Within this Review, we will outline
the biochemical and mechanical cues linked to BMEC
Figure 1. The cells of the NVU. BMECs form the lumen of the blood vessel
by wrapping around themselves, forming TJs with the BMECs either side.
Pericytes are discontinuously distributed along the CNS microvessels, par-
tially enclosing the vessels, and have been found to contribute to the bar-
rier properties of the BBB. BMECs and pericytes share a BM, named the
endothelial or perivascular BM. This is distinct from the parenchymal BM,
which splits the astrocytic end feet from the pericytes and BMECs.
Astrocyte end feet additionally coat the microvessels of the NVU with a
lacework of lamellae and additionally aid the BMECs in forming a barrier.
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barriergenesis and how these may be used to create in vivo-like
BBB in vitro models.
2. Biochemical Insights into Barriergenesis
The cells of the NVU display a clear biochemical interaction with
the microvasculature, as shown in Figure 2, and by the improve-
ment of in vitro TEER measurements through use of coculture
involving both immortalized, primary, and iPSC-derived
cells.[39–60] Bidirectional signaling between pericytes and
BMECs, and astrocytes and BMECs, leads to the formation of tight
junctions and barrier integrity into adulthood, which makes the
secretomes of both astrocytes and pericytes of great interest in
the search for barriergenic factors in the BBB.[4,7,10,61] The forma-
tion of the BBB can be broken down into three phases, consisting
of: 1) angiogenic, 2) barriergenic, and 3) maturation phases, each
of which are characterized by differing levels of angiogenic and
morphogenic biochemical signals, the latter two of which will
be explored in this section. In short, the angiogenic phase is driven
by vascular endothelial growth factor (VEGF) and angiopoietin
(Ang)-II-driven angiogenic sprouting in early embryogenesis.[62]
The recruitment of pericytes to the developing microcapillaries
is a critical step in the formation and maintenance of the BBB,
and much of the insight into their importance has been
ascertained from pericyte-deficient mice studies with PDGF-BB
disruptions.[7,63,64] In this barriergenic phase, angiogenic factors
are overridden by barrier-inducing signals, such as Sonic
Hedgehog (Shh), Norrin, PDGF-BB, and Ang-I.[62] While bio-
chemical signaling is key to the differentiation and formation
of the barrier, the molecular crosstalk needed for BBB maturation
andmaintenance is still an emerging field. As cells in in vitromod-
els maintain their barrier characteristics for a short period of time,
the maintenance of the barrier may require contacts with the cells
of the NVU; however, at this time this is pure speculation.[62]
While astrocytes are recruited at a later stage to further assist
BBB formation, and therefore are uninvolved in early BBB barrier-
genesis, the full extent of their role in BBB formation and main-
tenance remains murky waters, as regional genetic removal of
astrocytes shows little effect on BBB permeability, although their
role in the cross communication between cells of the NVU
shows astrocytic importance for maintaining an optimal BBB
phenotype[31,65–67] Below, we will discuss some of these biochem-
ical signals in detail as they have been shown to affect the BBB in
in vivo ablation studies and their ability to produce barriergenic
properties in vitro, which are further summarized in Figure 3.
Figure 2. Mechanisms of the bidirectional interactions between astrocytes, pericytes, and BMECs, as they aid the formation and maintenance of the BBB.
Of the mechanisms known to the authors, the majority depicted in this figure are concerned with overcoming proangiogenic forces, such as VEGF. Other
mechanisms induce the retention of pericytes in the NVU (PDGF-BB), preservation of the BM through inhibitingmatrix MMPs or through the differentiation
into favorable astrocyte phenotypes (LIF). Solid line represents a direct action, dashed line indicates that intermediary steps have been omitted for clarity.
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3. PDGF Signaling
PDGF is a potent mitogen which plays a significant role in blood
vessel formation. During CNS angiogenesis, BMECs recruit peri-
cytes to the nascent vessel by releasing PDGF-BB, a high-affinity
ligand for the PDGF-Rβ receptor found on both pericytes and
endothelial cells.[64,68] PDGF-BB secreted by BMECs binds to
two receptors, PDGFR-α and PDGFR-β found on pericytes,
although it is unclear whether PDGF-BB/PDGFR-α interaction
supports BBB integrity, the binding of which on pericytes leads
to the enhancement of BBB integrity.[69,70] PDGF signaling has
been shown to be involved in both vascularization in the brain
and pericyte recruitment and retention. The disruption of the
attachment of pericytes leads to BBB disruption as well as neuro-
inflammation and CNS disease.[49] While it is a known barrier-
genic factor, and numerous mice studies show the restorative
ability of PDGFR-β and -α after stroke (which involves BBB dis-
ruption), to our knowledge, no in vitro models utilize PDGF-BB
signaling, except in the form of pericyte/astrocyte cocultures. It
would be of interest to see whether PDGF-BB autocrine signaling
from BMECs is an effective instigator of barriergenesis.
While the PDGF interactions between pericytes and BMECs
play a key role in BBB formation, the BMEC–astrocyte interaction
additionally leads to the formation and maintenance of the bar-
rier. The endothelial-derived PDGF-BB caused the downregula-
tion of VEGF expression by astrocytes, a known disruptor of the
BBB.[71] This is caused by an upregulation of Gravin (the human
homolog to mouse SSeCKS), which was shown to further
markedly upregulate Ang-I, a potent vascular maturation factor,
which overall leads to the strengthening of the interendothelial
junctions, partially through the increased expression of TJ pro-
teins occludin and claudin-5.[49,71] Pericyte-BMEC PDGF-BBB
signaling therefore works not only to recruit and retain pericytes
but additionally reduce and overpower proangiogenic signaling
from nearby astrocytes.
In animal studies of the interaction of PDGF-BB and the BBB,
a decrease in the number of pericytes was seen, as a result of
reducing PDGF-Rβ signaling in mice through the deletion of
tyrosine phosphorylation sites or ECM retention motif compared
with wild-type littermates, which results in leaky vessels and
increased vascular permeability.[7,72,73] Counter to what might
be thought, the effect on vascular permeability was shown not
to be caused through compromised TJ protein expression, but
through defective regulation of endothelial transcytosis. The exis-
tence of large numbers of efflux transport systems in BMECs, as
well as the enzymatic barriers which exist, is one of the key rein-
forcers of BMEC barrier properties.
4. Wnt and B-Catenin Signaling
The name Wnt is a portmanteau from the names Wingless and
Int-1 and acts as the name for a group of signal transduction
pathways, which all begin from the binding of a Wnt-protein
ligand to a Frizzled (Fzd) family receptor.[74,75] The effectors
of the Wnt signaling pathway are highly upregulated in
BMECs in comparison with peripheral endothelial cells, such
as those in the liver and lung, which suggests the role of
Figure 3. Selection of signaling pathways activated by barriergenic growth factors and cytokines in BMECs. Pathways function primarily through three
pathways: 1) through increasing expression of junction proteins and 2) efflux transporters, and 3) prevention of angiogenesis. PDGF-BB signaling through
Rac1 maintains barrier function. FGF signaling additionally signals through the PI3K-AKT pathways as well as inhibits transcription regulator forkhead box
protein O1 (FOXO1) and occurs via the translocation of transcription factor Nrf2 into the nucleus, thereby increasing the expression of AJs and TJs. Wnt
signaling inhibits the breakdown of B-catenin as well as allows β-catenin translocation into the nucleus, where it causes the expression of many genes,
including TROY/DR6, which additionally causes barriergenesis to occur.
www.advancedsciencenews.com www.advnanobiomedres.com
Adv. NanoBiomed Res. 2021, 1, 2000068 2000068 (4 of 21) © 2021 The Authors. Advanced NanoBiomed Research published by Wiley-VCH GmbH
Wnts in the regulation of CNS microvasculature.[61,76] Wnt fac-
tors act in three known independent pathways, a canonical β-cat-
enin-dependent pathway and two non-canonical pathways.[74,76]
However, research has indicated that only canonical signaling
is important in barriergenesis, as well as essential for the devel-
opment of the brain microvessels.[61,76–81] Studies have shown
that the activation of the Wnt/β-catenin pathway is both neces-
sary and sufficient to induce BBB-type endothelial TJs in vivo
on both a molecular and a structural level.[78–81] While the use
of biochemical factors in lieu of co- or triculture conditions is
a field still emerging, Laksitorini et al. showed that in a BBB in
vitro model, utilizing immortalized BMECs, manipulating exog-
enous Wnt signaling through the inhibitor LiCl, or activating
Wnt signaling with Wnt3a improved P-gp efflux transporter
activity and decreased paracellular permeability, althoughmanip-
ulating the autocrine Wnt signaling of BMECs resulted in more
modest and minimal effects.[82] Overall, Wnt activators to date
have been shown to be an exciting avenue of exploration in
the creation of BBB in vitro models.
In the canonical pathway, the binding of Wnt to Fzd and
LRP5/6 results in the translocation of a stabilized β-catenin into
the endothelial cell nucleus and interacts with TCF/LEF-1 com-
plexes, which regulate the expression of specific genes. Genes
controlled in this manner in BMECs include glucose transporter
Glut1, a hallmark of the BMEC phenotype, as well as death recep-
tors DR6 and TROY, and TJ proteins claudin-5 and occlu-
din.[76,80,83,84] Tam et al. showed that the increased expression
of TROY and Dr6, which are downstream elements of the
VEGF pathway, drives brain angiogenesis and BBB formation
through the regulation of zonula occludens-1 (ZO-1) expression
in BMECs, independent of their canonical apoptotic and prode-
generative activity.[83] The ablation of β-catenin in endothelial
cells results in normal vascularization in all organs except the
CNS, where vessel formation fails, and BMEC accumulation
of β-catenin has been proposed to regulate the formation of
TJs via the increased expression of claudin-3.[61,79]
When looking at specific activators of the Wnt pathway in the
BBB,Wnt7a andWnt7b are shown to be particularly important in
BMECs and have been implicated in BBB development in
vivo.[61,77] Furthermore, genetic ablation in mice caused the fail-
ure of developing BMECs to invade the embryonic CNS, as well
as a lack of expression of proteins characteristic of the BBB.
Wnt7a b1 as well as Wnt3a have been shown to induce the
expression of claudin-3 and Glut-1.[61,80,85] Wnt5a was shown
to regulate endothelial cell survival, proliferation, and gene
expression.[78,86]
Norrin, a divergent member of the TGF-β superfamily, shows
high affinity of the Fzd4 receptor while sharing no homology
with Wnt family proteins and, through binding the receptor, acti-
vates the canonical Wnt pathway.[87] Norrin signaling upregu-
lates the expression of Glut-1 and claudin-5 in BMECs, while
downregulating proangiogenic markers, plvap/meca32.[87] The
genetic ablation of Norrin or Frizzled4 was shown to result in
defective angiogenesis in the CNS and barrier disruption.[88]
In a study on mice, when Norrin was expressed, loss or inactiva-
tion of Norrin or Frzd4 led to the loss of barrier characteristics
and upregulation with permeability-associated genes, plvap/
meca32.[62,87]
5. Hedgehog Signaling
The hedgehog (Hh) pathway is involved in embryonic morpho-
genesis, neuronal guidance, and adult vascular proliferation and
differentiation. The Hh pathway has been identified as playing a
key role in the expression of claudin-5 and maintenance of bar-
rier properties with the Hh family member Shh being the best
described with CNS morphogenic events.[65,89–91] Astrocytes are
the main Shh secretors in the CNS, which bind to the endothelial
patched homolog 1 receptor (Ptch-1), a 12-pass transmembrane
protein. The binding of Shh to Ptch-1 causes the release of the
inhibitory protein smoothened (SMO), allowing for the activation
of Gli family transcription factors and the expression of Shh-reg-
ulated genes such as claudin-5, VE-cadherin, and JAM-A.[65] The
selective deletion of SMO results in decreases in TJ protein
expression and is associated with the vessel leakage of plasma
proteins.[92] To our knowledge, no in vitro models of the BBB uti-
lize activators of the Hh pathway.
The maturation phase and type of astrocytes from which Shh
appears to have an effect on how Shh acts upon the BBB, with
Shh released by astrocytes in the adult BBB, contribute to the
integrity of the barrier, particularly during inflammatory disease
and Shh secreted by immature astrocytes, increasing the expres-
sion of occludin and claudin-5, as well as the regulation of these
genes.[65,89] During brain angiogenesis, Shh is secreted by astro-
cytes, resulting in a decrease in SMO activity in ECs that leads to
the decreased expression of TJ proteins such as occluding and
claudin-3 and 5, but also ZO proteins. This resulted in the
increased leakiness of the BBB. By regulating the expression
of p120-catenin, the Shh pathway may modulate the maturation
of both adherens junctions (AJs) and TJs in CNS vascular endo-
thelium.[65] Shh was shown to preserve BBB integrity by increas-
ing ZO1, occludin, and Ang-I expression in animal models for
ischemic stroke.[88] At a cellular level, Shh was shown to induce
the expression of Ang-I and repress Ang-II, which led to
increased expression via Tie1 and downstream junctional protein
expression and vascular maturation.[93]
In animal models for stroke, Shh is found to be transiently
upregulated in the focal ischemic brain.[94] In animal models
for acute ischemic stroke, loss of Shh signaling led to aggravate
brain edema.[94] As this research may suggest, intracerebroven-
tricular injections of Shh in ischemic stroke animal models
reduce brain edema and preserve the BBB integrity by inducing
expressions of ZO-1, occludin, and Ang-I.[89] Shh knock-out (KO)
mice are not viable and express with BBB formation abnormali-
ties, maintaining normal numbers of vessels but decreased
expression of occludin and claudin-5.[5] This data suggest that
Shh is not required for CNS blood vessel formation, but for mat-
uration of the BBB once vessels are formed, as well as maintain-
ing and repairing barrier characteristics in the BBB.
6. TGFB Signaling
The multifunctional cytokine, TGF-β, is a known disruptor of the
BBB; it has also been reported to cause the induction of claudin-5
expression in BMECs but also decrease claudin-5 expression in
BMECs. TGF-β promotes BBB integrity via enhanced endothelial
TJ protein expression, both in vivo and in vitro.[95,96] BMECs and
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pericytes adhesion are additionally mediated by the TGF-β and
TGF-β receptor 2 (TGF-βR2) by both cells, after the recruitment
and proliferation of pericytes at spouting vessels within the CNS
occurs via PDGF-BB.[68] In addition, deletion of TGF-β was
reported to result in embryonic lethality, pericyte loss, faulty vas-
cular development, and hemorrhaging.[97–99] While TGF-β is
often grouped with growth factors involved in BBB disruption
and stated to exacerbate BBB permeability in disease, there exists
a duality within the data that additionally show a potential for
maintenance of the BBB.
TGF-β signaling in pericytes initiates production of ECM pro-
teins and in BMECs promotes pericyte adhesion through N-cad-
herin. Within the TGF-β signaling cascade, Smad4 is a key
protein, and mice deficient in it show pericyte detachment
and increased vessel diameter, BBB permeability, and hemor-
rhage.[68] Garcia et al. showed experimentally that treatment of
cultured endothelial cells with TGF-β increased the activity of
BBB marker γ-glutamyl-transferase (GGT) in a dose-dependent
manner, which occurred concurrently with a reduction in the
number of endothelial cells, indicating an inverse relationship
between proliferation and GGT expression, which is consistent
with differentiation into BMECs forming a barrier.[100,111] A
study by Shen et al. indicated that TGF-β may be a downstream
effector of PDGF signaling and that PDGF’s pivotal role in BBB
restoration after cerebral ischemia may be in part due to PDGF
regulation of TGF-β signaling.[69]
GRP124, an orphan member of the G protein-coupled recep-
tor family, was identified as an essential endothelial receptor for
CNS-specific angiogenesis. Orphan G-protein coupled receptor,
Gr124, additionally acts as a specific coactivator of the Wnt/β-cat-
enin signaling pathway inn the BBB.[102,103] GRP124 signaling
induces Glut-1 expression and is required for TGF-β signaling
in BMECs.[104,105] Mice with GRP124 KOs are embryonic lethal,
with defects in the CNS vasculature with signs of hemorrhages,
which result from impaired endothelial cell survival, outgrowth,
and migration.[102,104,105] There appears to be some overlap
between Wnt signaling and GRP124, such as a lack of Glut-1
expression in KO mice, which may indicate some interaction
between these pathways during development.[61,80]
7. Fibroblast Growth Factor Signaling
Fibroblast growth factors (FGFs) are a family of growth factors
which are known to play key roles in angiogenesis, wound heal-
ing, and embryonic development.[106] FGF protects from BBB
breakdown through reduction of RhoA activity via the phosphoi-
nositide 3-kinase (PI3K) Akt-Rac1 signaling pathway.[107] In
experiments conducted by Reuss et al., the ablation of FGF-5
and FGF-2 in mice resulted in decreased levels of glial fibrillary
acidic protein (GFAP), an astrocytic marker, as well as BBB
breakdown.[108] Although the BBB research community has
established that FGF plays a vital role in brain physiology and
astrocytes, as it induces the proliferation and maturation of astro-
glia cells and activates astrocytes, there has been a long silence in
the FGF research and how it may induce barrier formation in
in vitro models.[108]
In an in vitro model which used slice cultures from mice,
Bendfeldt et al. found that FGF-2 (also known as basic FGF or
bFGF) helped preserve the cerebral vessels and maintained
the tight junctions.[109] FGF-2 is primarily produced by astrocytes
in close association with BMECs in the BBB and binds the FGF
receptor 1 (FGFR1) on BMECs.[110] Sobue et al. hypothesized
that the barrier-improving properties of astrocyte coculture
may be due to FGF-2 secretion by astrocyte; they did not find
a significant increase in the number of TJs, nor the expression
of mdr and Glut-1 in immortalized BMECs, although FGF-2
addition to media did increase the tightness of the barrier and
decrease L-glucose permeability (but not as much as coculture
conditions did).[110,101] FGF-2 was also shown to decrease in vitro
permeability by el Hafny et al.[112] It has also been hypothesized
to be one of the barrier-tightening factors by C6 glioma cells
in rats.[113]
There is a high level of colocalization of the FGFR1 receptor
with laminin in the BM and no colocalization of the receptor with
astrocytes.[109] This is in agreement that FGFR1 signaling is
dependent on the ECM composition in capillary EC differentia-
tion and that laminin plays a crucial role in this.[114]
8. Ang Signaling
Both Ang-I and II are released from astrocytes in the NVU,
where Ang-I binding the Tie2 receptor on BMECs results in
the upregulation and subcellular distribution of TJ proteins
and Ang-II binding AT1 is involved in the posttranslational mod-
ification of occludin and its subcellular distribution.[60,115,116]
Ang-I’s role in barrier stability was shown by Ang-I positively
regulating B-catenin in BMECs, through activation of Akt and
GSK2B phosphorylation, leading to the upregulation of Notch
signaling.[116]
9. Notch Signaling
Notch1, which is expressed by stalk cells within the neural niche,
leads to the suppression of an angiogenic phenotype and there-
fore leads to vessel stabilization and potential for barrier forma-
tion.[117] Notch signaling originating from pericytes additionally
binds Notch1 on the BMEC surface, which leads to the increased
expression of N-cadherin, increasing pericyte retention in CNS
vasculature.[118]
10. Other
Other relevant growth factors include cluster of differentiation
146 (CD146), glial cell line-derived neurotrophic factor
(GDNF), as well as apolipoprotein E (APOE). CD146 is a known
marker of the endothelial cell lineage, although it has also been
identified as a spatiotemporal molecule which orchestrates BBB
development as a critical regulator of claudin-5 expression and
BBB permeability. Pericyte expression of CD146 promotes the
pericyte coverage of ECs, as well as enhancing BBB integrity
more directly by regulating PDGF-BB/PDGF-Rβ signal-
ing.[119,120] GDNF is also known to increase claudin-5 expression,
although the mechanism through which it does this remains
unknown.[121,122] APOE secreted by astrocytes was also found
to be involved in the post-translational modification of occludin
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when it binds the LRP-1 receptor. APOE KOmice increased cere-
bral vessel permeability and the leakage of serum proteins into
the CNS.[123–127] The different APOE isoforms were also found to
have differing effects on the BBB, with APOE3 and APOE2 pro-
moting physiological BBB tightness and APOE associated with
disruption.[128] Adrenomedullin is a potent vasodilator and has
been shown to increase claudin-5 expression and increase
TEER and reduce the permeability of rat BMECs in vitro.[129]
Vascular endothelial (VE) cadherin, while not only contributing
to overall vascular stability, additionally plays a role in the endo-
thelial response to both pro- and antiangiogenic stimuli.[130]
11. Mechanical Cues in Barriergenesis
Most cells require cues from a 3D environment to form a physi-
ologically relevant tissue structure in vitro. At the most basic lev-
els, tissues are composed of a population of cells interacting with
their ECM. Cells are capable of remodeling their matrix during
morphogenesis and differentiation or under normal physiologi-
cal conditions, which are dictated to an extent by the matrix
mechanical properties (stiffness, viscoelasticity) and the interac-
tions of membrane cell receptors with their cognate extracellular
motifs formed between the cell and its surroundings.[131,132]
Compared with plastic or glass substrates, cells cultured on
matrix or matrix-mimetic substrates can induce the expression
of tissue-specific genes.[133]
The mechanical environment of cells is defined by complex
interactions between local forces, generated by the movement
of fluid/air pressure, gravitational forces; and intracellular ten-
sion, arising from the organization of cytoskeleton arrange-
ment.[131] The process of mechanotransduction can be broken
into 1) the initial force, such as shear stress produced by the
blood flow, 2) the detection of this force by cellular structures
in the cell membrane, 3) the transduction of these forces by sig-
naling molecules and the propagation of the signal, and finally
4) the reception by cellular receptors and the physiological
response.[130,134,135] Mechanical forces play an important role
in the physiology and development of every organ, and the endo-
thelial monolayer in the BBB is no exception. The endothelium is
exposed to two physical cues: the fluid shear stress (FSS) on the
apical face and ECM/BM nanoscale topography on the basal face
of the endothelium.[136] While pivotal in the formation of the
BBB, these forces have also been shown to play a role in vascular
pathology in the BBB.[130,136]
12. The Endothelial Mechanosome
In vitro investigations have highlighted the activation of multiple
mechanosensors in BMEC cell membranes in response to
mechanical cues.[135,137] These include integrins, tyrosine kinase
receptors such as G proteins and G protein-coupled receptors,
ion channels, caveolae, membrane lipids, glycocalyx, gap junc-
tions, focal adhesions, and proteins in the intracellular junctions,
namely VE cadherin and occludin.[135,136] Of these, VE cadherin
and PECAM-1 make up the mechanosensory complex situated in
the endothelial AJs.[137]
12.1. VE Cadherin
VE cadherin is responsible for the assembly of AJs and the main-
tenance of the BMEC monolayer integrity and plays a major role
in the assembly of the mechanosensory complex and as a mecha-
noadaptor to VEGFR-2.[138–140] Tzima et al. discovered the
mechanotransductory role of VE cadherin, showing that endothe-
lial cell alignment with the direction of the fluid flow required for
VE cadherin.[141] As shown below, since the discovery of its role
in endothelial cell response to flow, VE cadherin has become a
well-documented vascular mechanosensor.
VE cadherin is particularly important for the formation of sta-
ble AJs, in which VE cadherin couples to the actin cytoskeleton
and acts as a crucial mechanotransducer for mechanical sensing.
Cytoskeleton pulling on the adherin complex is known to
enhance cell–cell adhesion.[138,139,142] Actin dynamics further-
more control the assembly/disassembly of VE cadherin junc-
tions. In mature junctions, VE cadherin is linearly organized
in cells, supported by actin bundles running in parallel.
Remodeling driven by actomyosin contractions results in the for-
mation of discontinuous junctions connected to perpendicular
tensile actin bundles.[138,142] The equilibrium between these
two mechanisms is tightly controlled by Rac and Rho
GTPases. Rac GTPase activation supports linear junctions, cor-
responding to a release of tension from VE cadherin, and Rho
GTPase activation increases actomyosin-mediated pulling forces
on VE cadherin junctions.[141,143] In flow conditions, laminar
flow elevates the tension of the actin cytoskeleton, increasing
BMEC cell–cell interaction forces through Rho GTPase-depen-
dent alignment of actin fibers in the direction of the flow.[138,141]
VE cadherin is additionally responsible for AJ formation, which
is presumed to be essential for TJ formation and the BBB
architecture.[144]
VE cadherin expression levels and phosphorylation play vital
roles in the permeability of the BBB, with enhanced expression
promoting BMEC barrier function and the phosphorylation of
VE cadherin showing a strong correlation with impaired BBB for-
mation.[144] The signaling pathways culminate in a change of the
phosphorylation at key tyrosine, threonine, and serine residues
on TJ proteins, such as tyrosine phosphorylation on occludin,
which has been linked to BBB breakdown.[145] VE cadherin trans-
mits physiological cues through occludin via the activation of the
Tiam1/Rac1 signaling pathway, which promotes tyrosine
dephosphorylation, inducing barrier stabilization.[145]
Mechanical forces, such as laminar shear stress, have also been
shown to affect the expression of VE cadherin and cause upre-
gulation of occludin.[146]
VE cadherin in tight junctions provides both vascular stability
and endothelial polarity but additionally regulates the BBB endo-
thelial response to angiogenic stimuli.[62,140]
12.2. Integrin
Integrins have an established role in mechanotransduction, act-
ing as intermediaries in shear stress-induced signaling cascades
to activate Shc and c-Hun NH2-terminal kinases
(JNKs).[141,147,148] During brain development, angiogenic
BMECs express integrins α4β1 and α5β1 which bind to
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fibronectin and induce cell proliferation via the MAPK signaling
cascade.[149,150] However, in the adult mouse, endothelial cell dif-
ferentiation and overall vessel stabilization are promoted through
the binding of integrins α1β1 and α6β1 to laminin.[149]
12.3. PECAM-1
Platelet-derived cell adhesion molecule-1 (PECAM-1) contributes
to the maintenance of the endothelial barrier and is a key mecha-
notransducer that translates shear stress from laminar blood flow
into cell alignment with the direction of flow.[138,141,151]
Mechanoresponses in the endothelial layer are likely dependent
on the direct force exerted on PECAM-1, as shown through the
local application of tensional force on PECAM-1 which elicits
global cytoskeleton stiffening, which in turn leads to remodeling
of integrin-based adhesions.[138,152]
12.4. Other
Transmembrane proteins piezo1 and piezo2 have been identified
as critical components of mechanically activating ion channels
and have been brought forward as mechanotransduction mole-
cules in endothelial cells, as have YAP/TAZ, which relay
mechanical signals exerted by the ECM rigidity and cell shape
to the nucleus.[103]
13. Basement Membrane
The BM is a type of ECM found predominantly beneath endo-
thelial and epithelial cells. The vascular BM consists of a 3D net-
work of proteins, mostly consisting of laminins, collagen IV,
nidogen, and perlecan.[153,154] Other proteins are differently
expressed in the vascular BM depending on the physiological
and developmental state.[155] These include fibronectin, fibu-
lin-1 and -2, and collagen XVIII.[156,157] The development of
the BBB BM may be of interest, particularly in the roles of dif-
ferent BM constituents, and a hypothesized timeline of BM for-
mation is shown in Figure 4. The BM has many important
functions, such as cell anchoring, structural support, and signal
transduction.[158] Two types of BMs are found in the NVU, the
endothelial BM and the parenchymal BM, which are physically
separated by pericytes, although these are indistinguishable
under nonpathological conditions.[159] The thickness of the
BM has been reported to be in the range of 50–100 nm or
20–200 nm.[160,161] The importance in the ECM also lies in its
ability to wrap and accumulate secreted proteins, such as Wnt
proteins.[162,163] Changes in its composition can be observed
in both acute and chronic neuropathies, which are thought to
contribute significantly to disease pathogenesis.[160,161]
The vast majority of research on the BBB focuses on cellular
and molecular constituents, leaving the BM largely unstudied.
This is in part brought about by its intrinsic complexity, as well
as the lack of research tools.[18,164] In this section, the composi-
tion of the cerebral microvascular BM, as well as its effect on both
the formation and the maintenance of the BBB, with both genetic
KO and knock-down (KD) studies, as well as results achieved in
in vitro BBB models, will be discussed. Recent studies have
shown that the BM contributes substantially to the vascular
barrier function, particularly in the migration of leukocytes
through the vessel wall.[165–167] However, there is a significant
gap of knowledge on how BM proteins may differentially affect
BBB qualities within the same in vitro model, which would sub-
stantially benefit the field.
The three primary cells of the NVU, BMECs, pericytes, and
astrocytes, adhere to the BM via specific members of the integrin
or dystroglycan family.[168,169] The expression of dystroglycan is
found in BMECs and perivascular astrocytes within the adult
mouse brain.[170] β1- containing integrins were found to be
expressed by BMECs, pericytes, and astrocytes, and it is the inter-
action of β1-integrins with collagen IV in the BM that is corre-
lated to the expression of claudin-5 and increased BBB integrity
in vitro.[171]
13.1. Laminin
Laminin is a heterotrimeric protein composed of α, β, and γ
chains.[172] The combinations of these generate a large number
of laminin isoforms, although not all combinations have been
found in mammals.[173] The biological activity of laminins is
largely defined by the a-chain interaction with integrins.[174,175]
The formation of the vascular BM is dependent on the initial
self-assembly of laminin into a sheet, which is then linked via
nidogen and perlecan to collagen IV, aiding the formation of
a secondary polymer network by collagen IV.[176–178]
While BMECs, pericytes, and astrocytes all synthesize lami-
nin, they contribute different isoforms to the vascular BM.[164]
BMECs predominantly generate laminin-411 and laminin-511,
whereas astrocytes generate laminin-211, and pericytes contrib-
ute laminins containing the α4, α5, and γ 1 subunits.[159,179] Due
to this cell-specific expression, the parenchymal and endothelial
BMs differ in the distribution of laminins such as laminin-211 in
the parenchymal BM and laminins-422 and -511 mainly located
in the endothelial BMs.[155] Sixt et al. showed that the recruitment
of mononuclear cells within the perivascular space was correlated
with the laminin composition. For example, T cell recruitment
exclusively occurred when the endothelial BM contained laminin
a4 chains but not the a5 chains associated with the parenchymal
BM which has a restrictive or inhibitory function.[159] This is due
to the high affinity of integrin α6β1 of the T cells to laminin-411
and low affinity for laminin-511.[180,181] Blocking β1 interaction
in vitro increases vascular permeability through the decreased
expression of claudin-5.[62]
Very few, if any, in vitro models utilize laminin coatings or
laminin-based scaffolds in BBB models, which would be a very
exciting possibility for its potential use in producing strong
barriers.
Global KOs of most laminin subunits, including those found
in the BBB, lead to embryonic lethality, therefore preventing fur-
ther study on their effect on the BBB.[182,183] Conditional KO
lines targeting the γ1 laminin chain, a very common subunit
in laminin isoforms expressed in the BBB, have been very reveal-
ing of its role. When specifically depleted in astrocytes, deletion
of the laminin γ1 chain produced mice exhibiting weakened vas-
cular integrity, resulting in hemorrhages in small arterioles in
the hypothalamus, thalamus, and ganglia.[164,184] The signifi-
cance of laminin, in particular astrocyte-derived laminin, can
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be further shown in laminin α2 chain KO experiments.
Intracerebral hemorrhage and age-dependent BBB breakdown
were shown to be associated with astrocyte-derived laminin-
211 loss.[9,185] Mice lacking the laminin α2 chain show defective
BBBs, as shown by the presence of inflammatory cells in the
brain parenchyma, as well as changes in TJ protein organization
and reduced pericyte coverage.[186,187] These results suggest an
indispensable role of astrocyte-derived laminin in BBB mainte-
nance. Overall, the depletion of astrocyte-derived laminin was
associated with an increase in BBB permeability and decrease
in the expression of TJ proteins, changes that may be attributed
to the effect of astrocyte-derived laminin on pericyte differentia-
tion and maintenance of pericyte noncontractile state.[188]
In transgenic mice studies utilizing mice with laminin defi-
ciencies in smooth muscle cells and mural cells, BBB breakdown
and hydrocephalus were seen in the mural cell transgenic mice
but not in the smooth muscle cell transgenic mice.[189] This sug-
gests that pericyte-derived rather than smooth muscle cell-
derived laminin is the cause of these changes. Hydrocephalus,
a condition characterized by the build-up of fluid-containing cav-
ities within the brain, can itself cause BBB compromise, and
therefore it cannot be ascertained whether BBB disruption in
the mural cell mice is due to pericyte-derived laminin or second-
ary to hydrocephalus.[190] Laminin α4 null mutants are viable,
although they exhibit symptoms such as compromised vascular
integrity as well as hemorrhage at the perinatal, but not adult,
stage of development.[191] Loss of laminin α4 is thought to be
compensated for by laminin α5, which has been shown to rescue
hemorrhage phenotype in adulthood, when laminin α5 expres-
sion is seen.[164,192] Mice with specific KO of laminin α5 in endo-
thelial cells were shown to have a normal phenotype without any
obvious defects, supporting the laminin α4 and α5 compensatory
action hypothesis.[193] While good for the mice, this compensa-
tory action means that the role of laminin in the brain remains
largely unknown. However, Russo et al. interestingly found that
mice lacking laminin α5 lost the ability to respond to shear
stress.[194]
13.2. Collagen IV
Collagen IV is the most abundant component of the BM. It is a
trimeric glycoprotein comprising three α-chains, of which six
have been identified to date (COL4A1-6).[178] While most collagen
IV isoforms are spatially and temporally restricted, COL4A1 and
COL4A2 can be seen in practically all BMs and are conserved
across species.[195] As ablation of either is embryonically lethal,
studies investigating the effect of COL4A1-2 on the BBB BM uti-
lize more spatially restricted genetic tests.[196,197] Gould and cow-
orkers, by introducing a splice mutation which removes exon 41
in COL4A1 in both BMECs, pericytes and astrocytes individually,
showed that the relative contribution of the manor NVU cell
types could be seen.[196–198] Loss of exon 41 from astrocytes
caused mild intracerebral hemorrhage, whereas introducing
splice mutation in pericytes or BMECs resulted in fully penetrant
intracerebral hemorrhage.[196] Complementing this study, there
have been numerous investigations that utilized missense muta-
tions in COL4A1/2, resulting in varying degrees of intracerebral
hemorrhage severity as well as brain malformations.[197,199,200]
Taken together, these findings suggest a critical role of collagen
IV in vascular integrity, which is likely why it is the most com-
mon BM protein component in BBB in vitro models.
13.3. Nidogen
There are currently two identified nidogen isoforms in mam-
mals, nidogen-1 and nidogen-2.[177] The function of nidogen
within the BM is to stabilize the collagen IV and laminin net-
works, particularly nidogen-1.[177,201,202] Nidgen-1 additionally
Figure 4. Two models on the temporal deposition of the BM of the BBB. A) Pastor-Pareja and Xu showed that perlecan deposition is dependent on prior
collagen-IV presence in Drosophila.[231] This was supported by analysis of Col4a1 mutant mice,[277] Drosophila,[278] and C. elegans.[279] However, mech-
anisms for laminin-independent collagen IV recruitment to at least some BMs have been shown by Ramos-Lewis et al. and Jayadev et al.[279,280] B) Based
on the review by Thomsen et al. on the formation of the vascular BM (HSPGs, nidogen, laminin and collagen IV), with addition of Wang and Milner for
their theory on the role of fibronectin as the first deposited BM component in the BBB, followed by laminin and then the binding of HSPGs such as
perlecan and agrin.[205,281] While fibronectin briefly aids the recruitment and attachment of pericytes, this is then replaced by laminin. Laminin-mediated
collagen-IV assembly is the final step in formation of the BM.
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binds perlecan and fibulin.[203,204] While mice deficient in either
nidogen-1 or nidogen-2 are largely normal, thinning of the vas-
cular BM is seen compared with controls in nidogen-1 KO mice,
as well as neurological defects, which presented themselves as
episodes of involuntary movement, which largely resemble seiz-
ures.[201,205] Nidogen-2 is upregulated and redistributed in nido-
gen-1 null mice, although nidogen-1 expression does not affect
nidogen-2 null mice; this still indicates the existence of a com-
pensatory mechanism between the two isoforms.[206,207]
Nidogen-2 mRNA expression is significantly downregulated at
the postnatal age, implying the importance in embryogenesis
but not adulthood, which may explain the differences of compen-
satory upregulation in null mutants.[208] The deletion of both iso-
forms leads to severe BM defects and perinatal lethality.[209]
13.4. Perlecan
Perlecan is a large protein present in most BMs and has various
domains (I–V ) and motifs, allowing it to interact with a large ros-
ter of molecules.[210] These include ECM proteins and heparin-
binding growth factors, such as FGF-2 and VEGF, as well as per-
lecan core protein binding factors, such as PDGF subunit B
(PDGF-B).[7,175,211,212] Perlecan plays an important role in the
maintenance of BM integrity.[213]
While perlecan deficiency is embryonic lethal in mice, exhib-
iting complex phenotypes in many tissues, the BBB and its for-
mation were seen to be affected. This may indicate that in
embryogenesis, perlecan is dispensable in BBB formation,
although how it may affect the BBB in later stages remains
unknown.[214]
13.5. Agrin
Agrin is a heparin sulfate proteoglycan (HSPG) with several C-
terminal sites for splicing, denoted as X, Y, and Z in rats, and is
the most abundant HSPG in the vascular BM.[215] The isoform of
agrin present in vascular BMs, z0, lacks an amino acid insertion a
the COOH terminal of the protein.[215,216] Agrin may have a sup-
portive role in BBB formation, as it has been shown to accumu-
late in the BM during the developmental period when
permeability of blood vessels in the brain reduces.[215,217] This
is further supported by mice studies showing the localization
of AJs and associated proteins in BMECs with agrin, and that
has a stabilizing effect on AJs.[216]
Agrin KOs are embryonic lethal.[218] Interestingly, zþ isoform-
deficient mice were born with smaller brains and died shortly
after birth due to neuromuscular defects but additionally showed
lower levels of many other agrin isoforms, such as z0 reduc-
tion.[219] It is our understanding that there are no published in
vitro models of the BBB which utilize agrin coatings.
13.6. Fibronectin
Fibronectin is a major adhesive glycoprotein, known to be
involved in cell interaction with collagens, and is important in
development and wound healing.[149] Wang and Milner proposed
a model in which fibronectin promotes aspects of BMEC behav-
ior consistent with an angiogenic phenotype, including cell
survival, proliferation, and migration, unlike laminin which pro-
moted EC differentiation and stabilization.[149] While there is an
initial downregulation of Rho activity during cell spread and high
cytoskeleton dynamics, in cells cultured on fibronectin-coated
substrates, there is an increase in Rho GTP loading as cell spread
is completed. This correlates with focal adhesion and stress fiber
assembly and then eventual return to baseline.[220,221]
13.7. SPARC
SPARC, also known as osteonectin or BM-40, is a BM protein
investigated as a possible modulator of TEER in BMECs, shown
to have an antiadhesive effect on BMECs and reduce TEER.[222]
SPARC is predominantly antiadhesive and is expressed by astro-
cytes both in vivo and in vitro.[223–226] It has also been suggested
to be involved in cerebral endothelial cell differentiation.[227]
However, when endothelial cells are grown on inserts coated
with SPARC, it has a negative effect on TEER measurements
compared with controls.[222]
13.8. In Vitro Results
The importance of the BM proteins in the maintenance of the
tightness of the BBB has become evident, as confirmed by vari-
ous in vitro studies of cell cultures grown on protein-coated
Transwell inserts mimicking the BBB.[228] In a refreshing study
by Katt et al., different BM protein coatings were used in the
Transwell model, either on the membrane or on gels placed
on the Transwell membrane.[229] They found that the coverage
of human brain microvasculature endothelial cells (HBMECs)
on different collagen IV (COL IV) gels greatly depended on stiff-
ness, with their lower-stiffness gels and lower cell coverage
decreasing over time, in comparison with their stiffer gels.
TEER values additionally substantially decreased from
Transwell membranes when cells were coated on the less-stiff
collagen IV gels, although this may also be caused by the rough
surface morphology of the gels, which prevents the formation of
a seal along the sidewalls. They additionally compared different
BM coatings such as fibronectin, laminin, collagen IV, perlecan,
and agrin. BMECs grown on COL-IV gels were not fully conflu-
ent three days after seeding, and overall, the use of BM coating
increased cell coverage. Cells grown on perlecan, or on combi-
nations of perlecan with other tested proteins cells, showed poor
adhesion. Agrin gels, however, showed complete monolayers,
and the authors stated them as important in promoting the adhe-
sion of BMECs, although BMECs showed weak claudin-5 stain-
ing and poor barrier function. However, the addition of
fibronectin restored the barrier.[229]
Thomsen et al. set up to investigate whether the co- or tricul-
ture of murine BMECs affected the expression of different BM
proteins.[45] They found there was no significant difference in the
gene expressions of laminin-α5 nor COL4-α1, betweenmono and
coculturing conditions. In proteome analysis comparing BMEC
monoculture and coculture with glial cells, no statistically differ-
ent compositions of BM proteins were found. BMECs expressed
all the major BM proteins mentioned earlier, while also express-
ing laminin-421, SPARC, fibulin-1/-2, fibronectin, collagen-type
XVIII, and thrombospondin 1.
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Tilling et al. found that inserts coated in 1:1 type IV collagen
and fibronectin (FN), and FN and Laminin, showed higher TEER
measurements then the components alone, with FN/Laminin
showing the highest TEER values in porcine brain capillary endo-
thelial cell monolayers.[222]
14. Mechanical Properties of the BM and Barrier
Formation
The acellular BM may hold hidden insights into the formation of
the BBB. As the majority of current in vitro models utilize
Transwell inserts, which mimic none of the physiological prop-
erties of the native BBB BM, there exists a lack of understanding
on how different physical properties, such as topography, thick-
ness, and stiffness, affect the formation and maintenance of BBB
properties. For example, it is not yet understood as to why the BM
forms hexagonal electron-dense networks of collagen IV and
fibronectin.[192,223–226]
The effect of BM topography remains a topic of active research
and, particularly in terms of barriergenic properties, remains
incompletely understood. Both the topography, as a dense struc-
ture of interconnected protein networks, and the thickness of the
BM act as additional physical barriers for immune cell migration
across the BBB and permeability of large molecules. While stud-
ies of BM stiffness and topography are of particularly interest in
the vasculature, this is an emerging area of understanding,
although these are limited to major vessels, such as the aorta
and carotid artery, to date.[230,231] The measurement of BM stiff-
ness in vivo remains extremely challenging, although overall, it is
assumed that the BM stiffness is determined by a combination of
protein packaging and the hydration state of the BM.[232]
The biomechanical properties of the BM, such as thickness,
stiffness, and elasticity, are of particular interest in in vitro
BBB models, as vascular stiffening is associated with cardiovas-
cular pathologies as well as stroke.[233–237] However, our under-
standing of the mechanisms linking barrier permeability and
junctional disruption with matrix stiffness is still emerging,
largely due to the lack of appropriate in vitro models where such
tunable parameters exist.[138,238–242] The majority of in vitro BBB
modeling is still conducted on substrates with stiffnesses in the
MPa–GPa range, such as Transwell inserts, glass, and tissue cul-
ture plastic, whereas the proposed in vivo, brain ECM is
1 kPa.[232] Furthermore, our emerging knowledge of the elastic
properties of the BM is constantly being updated. While it has
previously been considered a purely linear elastic material, a
more recent study using breast gland BM concluded that the
BM acts more as a fluid-filled porous elastic solid.[138,240,243]
Therefore, when designing an in vitro mode, poroviscoelastic
frameworks may be considered to better represent the in vivo
BM mechanical behavior.
One driver of AJ junctional disassembly and vascular leakage
is increased contractility in BMECs, although actin fiber forma-
tion has also been tied to AJ presentation and barrier permeabil-
ity.[233,243,244] Studies have shown a link between the edge
presentation of VE cadherin and the formation and maturity
of both the barrier as a whole and the junctions between
BMECs. This is specifically true of linear VE cadherin structures
that run parallel to the cell boundary, not with discontinuous
focal adherens with serrated morphologies, which are indicative
of an immature junction.[233] BMEC AJ presentation has also
been shown to be modulated through the alteration of subendo-
thelial stiffness via myosin II-mediated contractility.[240] Soft sub-
strates and cells with low tension where shown to form stable,
linear AJs, whereas cells experiencing high tension or on stiff
substrates showed discontinuous junctions and increased per-
meability.[245] ZO-1 has been recognized as a regulator in cell–
cell tension and junctional assembly through the organization
of actomyosin and actin, which themselves are involved in the
cell response to substrate stiffness.[130,144,246] Gray et al. found
that junctional coverage, calculated using ZO-1 presentation,
was the lowest on glass and increased on 1 kPa hydrogels, show-
ing improved barrier properties on biologically relevant stiff-
ness.[247] The cells grown on glass showed their highest
contractility, which induced the poorest barrier properties of
all conditions tested, which improved in response to blebbistatin,
with decreasing contractility. This is supported in previous work
by Onken et al., that showed increased actin stress fibers in the
HBMEC cell line when seeded on polyacrylamide gels of increas-
ing stiffness, which correlated with immature VE cadherin
junctions.[240]
15. The Effect of FSS on BMEC
FSS, a tangential force caused by circulating blood, is a critical
factor affecting vascular remodeling, endothelial cell polarity, and
barrier properties.[144,248] The endothelial monolayer acts as a
transduction interface for hemodynamic forces, which can be
subsequently transmitted to the surrounding astrocytes, peri-
cytes, and microglia of the NVU.[130,144,246] The BBB dynamically
responds to FSS, with evidence that capillary-like shear stress
promotes BBB functions and facilitates the differentiation of
VE BMECs, with the defining characteristics of low permeability,
tight junctions, and low cell proliferation, as summarized in
Figure 5.[245,249]
At a cellular level, shear stress activates several flow-regulated
transcription factors, among which are Kruppel-like factory fam-
ily proteins (KLF2 ad KLF4), YAP, and NF-κB.[248,250–252] KLF2
and KLF4 are known to be expressed in response to laminar flow,
causing an increase in eNOS expression and reducing endothe-
lial permeability.[248] They further reduce the expression of
known inflammatory proteins. Mechanical stimuli also regulate
the cellular location of and translocation of YAP, unidirectional
laminar flow, causing nuclear translocation in a transient man-
ner, and disturbed or oscillatory flow, facilitating nuclear trans-
location in a more sustained manner.[248,251]
At a larger scale, VE cells outside the brain microvessels
become elongated and aligned with the blood flow through a pro-
cess of the redistribution of junctional proteins. BMECs report-
edly do not deform from their cobblestone morphology under
mechanical shear stress.[253–256] It additionally promotes cell
adhesion through increase in integrin–ligand binding and indu-
ces cell alignment in the direction of flow. This is due to the
increased expression of TJ and AJ proteins in BMECs, particu-
larly ZO-1, which is advantageous to BMEC barrier properties
and prevents morphological transitions, such as elonga-
tion.[257–259] While this offers to be a promising avenue in
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BBB in vitro model creation, evidence suggests that cell source
should be considered. Andrews et al. reported that the initiation
of mechanotransduction in adult BMECs and fetal BMECs may
be prevented by transformation into an immortalized D3 cell
line.[260] It would be of interest to produce a series of thorough
experiments by comparing and contrasting immortalized BMEC
cell lines to the iPSC-counterparts, in particular in regard to the
use of shear stress as a barriergenic agent so as to establish
within the BBB community preferred cell line.
A large FSS range has been reported for brain capillaries, from
5–23 dyne cm2 in humans to 20–40 dyne cm2 in rats.[130,261]
The evidence indicates that capillary-like shear stress promotes
BBB functions and facilitates the differentiation of the BBB phe-
notype in VE cells, while additionally increasing the tightness of
the endothelium and control of substance exchange at the blood–
brain interface.[146,245,249] Physiological laminar shear stress is
known to increase the expression of tight and adherent junctions,
expression of related RNAs, drug efflux transporter genes, and
causes an increase in TEER values, as well as localization of tight
junction proteins to the cell–cell junctions through cytoskeleton
reorganization.[145,146,245,249,262] Laminar shear stress also inhib-
its proliferation of endothelial cells which is early marker in cell
differentiation.[245,263]
A physiological-like shear stress of 8 dyne cm2 furthermore
relieves the disruptive effect of interleukin (IL) on BMECs.[257]
This was further evidenced by research showing the disruptive
effect physiological shear stress has on tumor necrosis factor-a
(TNF-a) and IL-6 and the reversibility of this under high shear
stress.[249,264] Garcia-Polite et al. additionally observed the
increased expression of TJ-related genes, adhesion molecules,
drug transporters, and integrins related to the BBB phenotype,
as well as an overall increase in cytoskeleton protein content
at 6.2 dyne cm2 shear stress.[262] However, low shear stress
(both 4 and 12 dyne cm2) was shown to have no effect on the
expression nor localization of TJ proteins claudin-5, occludin,
or ZO-1 in iPSC-derived HBECS.[257] In response to
10–20 dyne cm2, BMECs were shown to upregulate TJ proteins
ZO-1 and claudin5, as well as BBB formation indicator, p-GP. At
10 dyne cm2, these were shown to have increased localization to
cell–cell borders.[265] There is additional increase in several
cytochrome-450 enzymes, which have been suggested to regulate
the entry of substances to the brain in an interdependent
manner.[257,258] Rochfort et al. further showed that the suppres-
sion of nicotinamide adenine dinucleotide phosphate (NADPH)
reactive oxygen species (ROS) production was stabilized in phys-
iological shear stress conditions. This was accompanied with
increased expression and decreased tyrosine and threonine
phosphorylation of TJ and AJ proteins.[262,266] It has also been
suggested that laminar shear stress decreases the negative effects
brought on by proinflammatory cytokines through the produc-
tion of a compensatory antioxidant defense. This neutralizes
ROS as well as inhibits thioredoxin-interacting proteins.[262,267]
Just as there is substantial evidence on the protective effects of
physiological flow, the pathogenic effect of disturbed flow and
high shear stress and its ability to increase oxidative stress
and inflammation, characterized by increased expression of
Figure 5. Effect of physiological shear stress on BMECs. Physiological shear stress acts both as an inhibitor of ROS-mediated inflammation and as barrier
disruption, as well as increases expression and localization to cell–cell junctions of TJ and AJ proteins. The pathway through which the increase in AJ and
TJ protein expression occurs appears to be largely unknown, although the increased expression of ZO-1 and therefore cell–cell junction localization of
occludin, and potentially claudin-5, occurs through the AKT-FOXO1 pathway. It further allows for cytoskeleton reorganizing and intracellular tension.
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inflammatory cell-anchoring proteins such as VCAM1, has also
been shown.[268] Steady flow inhibits VCAM1 by increasing anti-
oxidant mechanisms and blocking inflammatory signaling
through inhibiting TNF-mediated activation of ASK1 kinase1-
JNK/p38 pathway.[262,268] Proinflammatory cytokines TNF-a
and IL-6 induce the activation of NADPH oxidase, therefore lead-
ing to the generation of ROS in VE cells. NADPH oxidase-depen-
dent ROS has been shown to increase paracellular permeability
through the reduction of expression and the disassembly of inter-
endothelial AJ and TJ proteins.[266]
High shear stress is sensed by G protein-coupled receptors,
which subsequently activate Src and ERK1/2.[235,262] There has
been a recent advancement in understanding the flow sensitivity
of the tyrosine protein kinase (Src)/extracellular signal-related
kinase (ERK1/2) pathways in VE monolayers. Under physiologi-
cal conditions, these are inhibited, and there is an additional
upregulation of TJ markers, but pulsatility and high shear stress
lead to downregulation of TJ markers.[144] In a high shear stress
model (40 dyne cm2) and pulsatile flow model, Garcia-Polite
et al. showed the downregulation of TJ marker expression and
ZO-1 translocation into the nucleus.[262] ZO-1 translocation to
the nucleus is inversely related to the number and maturity of
cell contacts, and can be a trigger for barrier loss, as ZO-1
protein downregulation is consequently followed by claudin-5
downregulation.[244] There is further decrease in the expression
of P-gp.[31,262]
ECM metalloproteinases (MMPs) substrates include compo-
nents of TJs and AJs as well as the ECM which surrounds endo-
thelial cells and pericytes in the BBB.While MMP expression in a
healthy brain is relatively low, both clinical and experimental
studies have shown that MMP-9, 3, and 2, among others,
are activated and upregulated after ischemia, which is accompa-
nied by an increase in BBB permeability.[269]
16. Geometry
While the influence of curvature on BMECs in BBB in vitro is
largely unexplored, the cylindrical geometry of microvessels
imposes curvature, which may be a very intuitive effect of cylin-
drical geometry, but additionally limits the number of cell–cell
interactions. Growing on a flat surface offers cells more cell–cell
contacts than cylindrical geometries, where cells are limited to
contacts with the cells either in the side in the cylinder and them-
selves.[270–272] BMECs in confluent monolayers were shown to
resist elongation and alignment due to curvature, a trait which
likely evolved to limit the total length of cell–cell junctions in
a given length of a blood vessel. This was found to be different
than other ECs, which minimized the effect of the curvature
through elongation and alignment, further supporting this diver-
gence between BMECs and other ECs.[272] Cylindrical geometry
and shear stress are not prerequisites to achieve TJ formation,
although there is potential for them to enhance or reduce the
GF requirements when making an in vitro BBB model.[270–272]
Overall, while cylindrical geometry increases the complexity of
in vitro models, it provides some promising avenues for those
brave enough to explore it, and there is space for more novel
research in this area regarding the BBB.
17. Hypoxia
Hypoxia was seen as a promising method to induce barriergen-
esis after in vivo studies showed that barriergenesis occurred
under hypoxic conditions during embryonic development.[273]
In their iPSC-based BBB chip, Park et al. found that hypoxic con-
ditions during the iPSC differentiation protocol produced a sig-
nificant increase in cell–cell adhesion molecule mRNA levels and
improved barrier qualities, such as higher TEER values.[272] It is
thought that these improvements to barrier properties arise from
the interplay between the Wnt/B-catenin signaling cascade with
hypoxia-induced factor 1a (HIF1a) signaling, which Park et al.
were able to show through upregulation of HIF1a in their hyp-
oxic conditions.[274] This offers a potential work-around for the
induction of hypoxic conditions, as HIF1a-mimetic or stabilizing
compounds can be used in addition to or instead of the use of a
hypoxic chamber.
While improved barrier properties have been seen in iPSC-
based BBB in vitro models when exposed to hypoxic conditions,
it should be noted that these are seen exclusively in iPSC cells,
and the opposite effect has been seen in non-iPSC cell lines.[257]
Fischer et al. showed VEGF/VEGF receptor-mediated permeabil-
ity induced by hypoxia in primary porcine BMECs.[275] It was fur-
ther shown that hypoxia-induced permeability could by inhibited
by YC-1 through inhibition of HIF-1a accumulation as well as
VEGF production by hypoxia-treated immortalized rat
BMECs.[276] While promising, there are a lack of similar studies
to support their findings on improved barrier properties after
hypoxic treatment, and whether this can substantially and con-
sistently improve and prolong barrier properties remains to be
seen.
18. Conclusion and Perspective
One major conclusion from the analysis from the known barrier-
genic factors is that the greatest barrier that researchers in the
BBB field face, especially for in vitro dynamic models, lies in
benchmarking the models. As shown in Table 1, the dynamic
BBBmodeling community is the Wild West of in vitro modeling,
with a wide variety of BBBmetrics used, making a comparison of
these models, or the large range of FSS they use, near
impossible.
To combat this lawlessness, the community at large should
consider standardized measurements that should be seen as a
prerequisite for publication. While TJ visualization and quantifi-
cation, either through Western blot or immunofluorescence, is
the easiest quantification method to use in dynamic in vitro mod-
els, these are, for the purpose of comparison across models, qual-
itative data. In terms of quantitative barrier property
visualization, TEER measurements seem to be the optimal solu-
tion, given that these are used to benchmark static models like
Transwell. However, due to the different methods of measuring
TEER in the papers shown in Table 1, which may not be compa-
rable, as well as the difficulty in implementing these in dynamic
models, TEER measurements may not be as useful in the
dynamic in vitro model field. We consider the use of permeability
assays to be an easy comparison of the barrier formation in these
models. It is likely that in time, the field gravitates to certain
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Table 1. Breakdown of barrier quantification in in vitro models utilizing FSS..
Measure for BBB characteristics Reporting of BBB characteristics References
Permeability 70 kDa fluorescent-conjugated




Permeability Permeabilities reported as “percentage change” between static control and FSS
condition.
Decreased permeability in response to FSS.
TEER
Reported graphically, 500Ω cm2 (coculture conditions).
TJ Immunofluorescence







No reporting of relevant data on the effect on FSS on BMEC and barrier properties. [282]
TEER TEER






quantitative polymerase chain reaction
(qPCR)
ABCN1, CDH5, CLDN5, OCLN, SLC2A1, TJP1
TJ Immunofluorescence
No clear difference between 4 dyne cm2 and static conditions.
Western blot
No significant difference between shear conditions and static for CLDN-5 and LAT-1.
ZO1 expression decreased at 4 dyne cm2 compared with the static condition.
qPCR






Decreased permeability in hollow-fiber model in comparison with Transwell model.
[283]
Permeability
C14 Sucrose (342 Da)
TEER
Study on the effect of normoxia–normoglycemia or hypoxia–hypoglycemia and IL-6 and TNF-a
release, not of the effect of shear stress.
TEER




10 kDa Dextran-Aexaflour 647
Permeability







TEER from Transwell insert to BBB chip (from 28.2 1.3Ω cm2 to 36.9 0.9Ω cm2)
TJ Immunofluorescence
Used to verify the presence of BMECs in the correct channel.
[284]
Permeability

















Not shown for conditions without TNF-a or IL-6 added.
TJ Immunofluorescence










Permeability calculated as fold change from static conditions.
Reduced permeability in response to shear stress compared with static conditions.
TJ Visualization
Greater localization to cell–cell junctions at 10 dyne cm2 than in static conditions or after 24 h, it is
reduced by 1 dyne cm2
Western blot
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molecular weights of molecules used to measure permeability of
the barrier. While dynamic in vitro models of the BBB are an
emerging field, the inability to compare models across papers,
the effects of different conditions, does the field a great
disservice.
A second conclusion is that there appear to be many avenues
through which barrier formation may be induced in BMECs, and
the field appears to be at an exciting precipice of discovery. This is
provided experiments comparing the relative effect on barrier
formation of different signaling pathway activators, BM protein
coatings, scaffold stiffnesses, and FSS. Despite substantial prog-
ress and numerous inspiring in vitro models, we still lack
answers to major questions.
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